Investor Alert

New York Markets Close in:

The New York Post Archives | Email alerts

March 9, 2021, 2:19 a.m. EST

Pfizer-BioNTech vaccine neutralizes Brazil COVID-19 variant, study shows

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    BioNTech SE ADR (BNTX)

or Cancel Already have a watchlist? Log In

By Kenneth Garger

The Pfizer coronavirus vaccine is able to neutralize a rapidly spreading  virus variant from Brazil , according to a new laboratory study.

Researchers developed an engineered version of the COVID-19 mutation and found that blood samples taken from people who received the vaccine were able to neutralize the variant, according to the study published in the New England Journal of Medicine on Monday.

The scientists from Pfizer /zigman2/quotes/202877789/composite PFE +1.40% , BioNTech /zigman2/quotes/214419716/composite BNTX +2.75% , and the University of Texas Medical Branch said the vaccine was roughly as effective against the Brazilian variant as other less contagious virus versions from last year.

Earlier studies found that the U.K. and South Africa COVID-19 variants were also neutralized by the Pfizer vaccine.

Read: What can you do after you are fully vaccinated? The CDC finally has an answer

But the South African variant, according to studies, may diminish protective antibodies induced by the vaccine.

Pfizer said it is planning additional tests on the South African variant.

A version of this report appears in The New York Post

$ 39.58
+0.55 +1.40%
Volume: 14.54M
April 21, 2021 12:53p
P/E Ratio
Dividend Yield
Market Cap
$217.72 billion
Rev. per Employee
US : U.S.: Nasdaq
$ 160.48
+4.30 +2.75%
Volume: 1.58M
April 21, 2021 12:53p
P/E Ratio
Dividend Yield
Market Cap
$37.72 billion
Rev. per Employee

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.